28  The Clinical Study Report

When a clinical trial ends, its findings must be distilled into a single document: the Clinical Study Report, or CSR. This document tells the complete story of the trial: what was planned, what was done, and what was found. It is the definitive record that regulatory agencies will examine when deciding whether to approve a new therapy.

The CSR serves multiple audiences with different needs.

28.1 The ICH E3 Structure

The structure of CSRs follows international guidelines, primarily ICH E3, which establishes a standardized format for presenting clinical study results. Table 28.1 shows the major sections.

Table 28.1: ICH E3 Clinical Study Report Structure
Section Content Typical Length Key Elements
Title Page/Synopsis Summary of entire study 2-3 pages Design, key results, conclusions
Introduction Background and rationale 2-5 pages Disease context, drug mechanism, program fit
Study Objectives What trial was designed to determine 1-2 pages Primary, secondary, exploratory objectives
Investigational Plan Study design details 10-30 pages Randomization, blinding, dosing, procedures
Study Patients Who enrolled 10-20 pages Disposition, demographics, baseline characteristics
Efficacy Results Primary and secondary analyses 30-100 pages Endpoint analyses, subgroups, sensitivity
Safety Results AEs, labs, vitals 20-50 pages AE tables, SAE narratives, lab shifts
Discussion Interpretation of results 5-10 pages Clinical significance, limitations, context
Conclusions Key findings 1-2 pages Summary statements
Appendices Supporting materials 100-1000+ pages Protocol, SAP, TLFs, patient listings

The CSR opens with a title page and synopsis: a condensed summary of the entire study, typically two to three pages, providing key information about design, results, and conclusions for readers who need a quick overview.

The introduction establishes context: the disease being studied, the rationale for the investigational product, and how this study fits into the overall development program.

Study objectives specify exactly what the trial was designed to determine. Primary objectives typically address efficacy questions; secondary objectives may address safety, pharmacokinetics, or other endpoints.

The investigational plan describes the study design in detail: the type of trial (randomized, controlled, blinded), the treatment groups, the dosing regimen, the duration of treatment and follow-up. This section also describes the patient population through the inclusion and exclusion criteria.

The study population section reports who actually enrolled: how many patients were screened, how many were randomized, how many completed the study, and how many discontinued (with reasons). Demographic and baseline characteristics are presented to establish that the study population matches the intended population.

Efficacy results present the primary and secondary endpoint analyses. Typically, this includes the primary efficacy analysis, sensitivity analyses, and subgroup analyses. Figures and tables display the data; text interprets the results.

Safety results present adverse events, serious adverse events, laboratory abnormalities, vital signs, and any other safety parameters collected. Events are tabulated by treatment group, and notable events are discussed in narrative form.

The discussion interprets the results in context: what do the findings mean for the investigational product, for the disease being treated, for the overall development program?

Conclusions summarize the key findings and their implications.

Appendices (which may constitute the bulk of the document) include the protocol, statistical analysis plan, patient data listings, and other supporting materials.

28.2 The Writing Process

Producing a CSR is a multidisciplinary effort that typically spans several months. At the center of this process are the medical writers, who synthesize information from the locked database, the statistical analysis plan (SAP), and the tables, listings, and figures (TLFs) generated by the biostatistics team. Biostatisticians provide the quantitative backbone of the report, while clinical operations teams contribute context on trial execution, site audits, and operational challenges that may have affected the data.

Medical and scientific reviewers ensure the clinical narrative remains coherent and scientifically sound. Regulatory affairs specialists oversee the document to confirm it meets submission requirements and supports the intended marketing application. This collaborative workflow typically proceeds through defined phases: teams first establish a CSR “shell” or outline; then, as statistical outputs become available, the medical writers integrate results into the draft; finally, the document undergoes multiple rounds of review and quality control before finalization for regulatory submission.

Accelerated Production: The CSR Shell

Experienced development teams often front-load the writing process by creating a “CSR Shell” months before the trial concludes. By drafting the introduction, study objectives, and investigational plan sections while the trial is still active, teams can significantly reduce the drafting bottleneck that typically occurs once the database is locked. This proactive approach allows for early internal reviews of the study’s background and methodology, ensuring that only the results and discussion sections require intensive drafting once the final data sets are available.

Abbreviated Reporting Options

Not every clinical study warrants a full technical report. Under ICH E3 guidelines, abbreviated CSRs may be used for trials with negative outcomes, those intended solely for exploratory internal decision-making, or studies terminated early. In these cases, narrative sections such as detailed medical background or extensive investigator biographies may be summarized or omitted. This allows the sponsor to preserve the trial’s core results and safety data within the Trial Master File without producing a full publication-quality report.

28.3 Quality Standards

Clinical study reports are held to exacting quality standards that underpin the integrity of the regulatory submission. Accuracy is essential: every figure and data point in the report must match the underlying analysis datasets, as any discrepancy can erode reviewer confidence. Internal consistency requires that results sections align with stated objectives and that terminology remains uniform across the document. Completeness matters equally, since missing regulatory elements can trigger delays and supplemental inquiries. Transparency requires an honest appraisal of the trial’s limitations and unexpected outcomes; any attempt to minimize safety signals or obscure unfavorable findings will likely be discovered by inspectors, damaging the sponsor’s long-term credibility (International Council for Harmonisation 1995).

The era of the CSR as a purely confidential document is ending. Driven by demands for scientific transparency and ethical obligations to trial participants, regulators are increasingly requiring public disclosure of clinical data.

The EU Clinical Trials Regulation (CTR) 536/2014 introduced a mandatory requirement for sponsors to provide a summary of results for laypersons (European Medicines Agency 2022). This document must be written in plain language suitable for the general public and typically includes the trial’s rationale, who participated, what happened, and the side effects and benefits observed. Drafting these summaries requires a specific skillset to simplify complex medical terminology without losing scientific accuracy.

Beyond summaries, extensive data redaction and publication policies such as the EMA Policy 0070 require the proactive publication of clinical reports once the regulatory decision is made. This process involves sophisticated anonymization techniques to protect participant privacy while retaining data utility. Sponsors must perform quantitative risk assessments to demonstrate that the risk of re-identification is negligible before these documents are posted to public portals.

28.4 Statistical Communication and Bayesian Reporting

From p-values to Probability Statements

The standard CSR statistical narrative reports a test statistic, a p-value, and a confidence interval. This format answers the question “Is the observed difference statistically significant?” It does not directly answer the question most relevant to regulators and clinicians: “How probable is it that this drug provides a clinically meaningful benefit?”

When a trial uses conventional frequentist methods and the p-value is clearly below or above the threshold, the distinction between these two questions rarely matters for regulatory decisions. It matters more in two cases: when the result is near the threshold (a p-value of 0.04 in one trial or 0.06 in another carries very different narrative weight despite containing similar evidence), and when the trial uses Bayesian methods whose natural output is a probability statement rather than a test statistic.

For Bayesian trials, the CSR should report the primary result in the same language the protocol and SAP specified: the posterior probability that the treatment is superior to control, the posterior probability of a benefit exceeding a clinically meaningful threshold, and the credible interval for the treatment effect estimate. The FDA review of REBYOTA (an approved fecal microbiota product) reported a 99.1% Bayesian posterior probability that the product was superior to placebo rather than a p-value, with FDA reviewers examining the full posterior distribution across effect-size thresholds (US Food and Drug Administration, Center for Biologics Evaluation and Research 2022). This represents a documented regulatory precedent for what Bayesian reporting in a submission document can look like.

For frequentist trials, the effect size and its confidence interval are equally important as the p-value and should appear in the abstract, the summary of efficacy findings, and the conclusions. A result that achieves p = 0.03 with a confidence interval that includes a hazard ratio of 0.99 (nearly no clinical effect at one end) is meaningfully different from p = 0.03 with a confidence interval entirely below 0.85. Both are “significant,” but the clinical interpretation differs substantially, and both the lower and upper bound of the interval should be discussed in the CSR narrative.

Communicating Uncertainty

A CSR that communicates only point estimates and binary pass/fail verdicts underserves the regulatory reviewer and downstream decision-makers. Reviewers at FDA and EMA are trained statisticians who will read the statistical appendix, but clinicians, health-technology assessment bodies, and prescribing physicians will rely primarily on the executive summary and the conclusions. Those sections should communicate the effect size in clinically interpretable terms (what a hazard ratio of 0.78 means for a patient’s risk over a year), the range of plausible effects in the same terms, and the consistency of the primary result across pre-specified subgroups and secondary endpoints. For Bayesian analyses, the executive summary should also report the sensitivity of the conclusion to the prior specification, demonstrating that the conclusion holds across alternative priors.

The aducanumab program (discussed in Chapter 27) demonstrated what happens when CSR reporting does not adequately address the discordance between two trials. A CSR for a trial with unexpected results should explicitly address whether the result is consistent or inconsistent with prior evidence, what alternative interpretations exist, and what additional information would be needed to resolve the uncertainty.

Reporting Adaptive Trial Results

Adaptive trials present additional CSR challenges. The standard CSR template was designed for fixed-sample trials, and CSRs for adaptive designs must additionally document:

  • The adaptation rules as pre-specified in the protocol and SAP
  • Which adaptations were triggered during the trial (with dates and data cuts)
  • The unblinded interim analysis reports (often as appendices, with access controlled per the charter)
  • How the alpha-spending or error-control method ensures the reported p-value remains valid despite the adaptations
  • The final sample size relative to the original plan and the reason for any deviation

For platform trials, the CSR for a single arm must make clear that the arm’s primary analysis used a shared control arm and describe the concurrent controls and non-concurrent controls (if any) that contributed to the primary comparison, with the dates of contribution and the time-adjustment method applied.

28.5 Integration with Regulatory Submissions

The CSR does not stand alone; it is part of a larger regulatory submission.

In the Common Technical Document (CTD) format used for major regulatory submissions, CSRs appear in Module 5 (Clinical Study Reports). The CTD also includes summaries and overviews that synthesize information across multiple studies (International Council for Harmonisation 2016).

For pivotal studies, the CSR will receive intense scrutiny. Reviewers will examine methodology, verify that the analysis followed the pre-specified plan, and assess whether the conclusions are supported by the data.

For supportive studies, the review may be less intensive, but the CSR must still provide sufficient information for the reviewer to understand what was done and what was found. The CSR remains the trial’s authoritative record long after the trial concludes.